Amgen Capitalizes on Success with No Major Changes to Portfolio Since 2022, Complements With Otezla Acquisition in 2019.
January 18, 2023
Trending News ☀️
Amgen Inc ($NASDAQ:AMGN). is a biotechnology pioneer, with a market capitalization of $145 billion, and one of the 30 stocks comprising the Dow Jones Industrial Average index. It has been a leader in developing innovative treatments for serious illnesses for over four decades. With a comprehensive portfolio of approved biologic drugs, Amgen has established itself as an industry leader in the biopharmaceuticals space. Since the last portfolio coverage prior to 2022, Amgen has not seen major changes to its portfolio, with the exception of its $13.4 billion acquisition of worldwide rights to Otezla in 2019. This move enabled Amgen to expand its presence in the inflammatory disease treatment space, adding an already approved treatment to its lineup. Otezla helps to provide relief from the symptoms associated with plaque psoriasis and psoriatic arthritis, two common inflammatory diseases.
The acquisition of Otezla has enabled Amgen to capitalize on the success of its existing portfolio, which includes treatments for cancer, cardiovascular disease, inflammation, and bone health. By expanding its offerings in the inflammatory disease space, Amgen can better serve the needs of patients with these conditions. Amgen’s commitment to innovation and providing solutions for serious illnesses is evident in its portfolio. It is clear that Amgen is trying to capitalize on its success and is looking to grow and diversify its portfolio. With the addition of Otezla and its other treatments, Amgen is well-positioned to continue to meet the needs of patients and help improve the lives of those suffering from serious illnesses.
Stock Price
On Tuesday, AMGEN INC stock opened at $272.2 and closed at $269.4, down 0.8% from its previous closing price of 271.7. In 2019, AMGEN INC acquired Otezla, a biopharmaceutical company specializing in treatments for inflammatory conditions. The acquisition is expected to contribute significantly to AMGEN’s portfolio, as Otezla’s portfolio includes several promising drugs that have the potential to be market leaders.
Overall, AMGEN INC has had a successful run since 2022 without making any major changes to its portfolio. Going forward, AMGEN INC looks poised to capitalize on its success and continue to deliver strong returns for shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Amgen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 26.33k | 6.83k | 26.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amgen Inc. More…
| Operations | Investing | Financing |
| 9.88k | -2.8k | -9.55k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amgen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 63.7k | 60.05k | 6.85 |
Key Ratios Snapshot
Some of the financial key ratios for Amgen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.0% | -1.2% | 34.4% |
| FCF Margin | ROE | ROA |
| 34.2% | 186.4% | 8.9% |
VI Analysis
AMGEN INC is a publicly traded company and its fundamentals reflect its long term potential. The VI Risk Rating suggests that, in terms of financial and business aspects, AMGEN INC is a medium risk investment. This means that while the company has some potential for growth, there are some risks associated with the venture. The VI App has identified two risk warnings in the income and balance sheets of the company. These warnings are meant to alert potential investors of any underlying issues with the company, such as cash flow issues, debt-to-equity ratio and liquidity ratios. It is important to understand that the risks associated with a company can change over time. As such, investors should not rely on the VI Risk Rating of a company as a sole source of information. Instead, they should consider other factors such as market conditions, industry trends and the quality of management. Investors should also be aware that the rating provided by the VI App only reflects the current state of the company and does not guarantee future performance. Therefore, it is important to do your own research and make an informed decision before investing in any company. By becoming a registered user of the VI App, investors can access additional information and analysis on AMGEN INC and other companies. More…
VI Peers
The competition between Amgen Inc and its competitors is fierce. Amgen Inc is the largest biotechnology company in the world, with a market capitalization of over $100 billion. Its competitors, Gilead Sciences Inc, Eli Lilly and Co, and Biogen Inc, are all large, well-established companies with significant resources. each company is striving to develop the best products and to gain market share. The competition is intense, and each company is working hard to win.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences Inc has a market cap of 83.2B as of 2022, a Return on Equity of 24.03%. The company’s key products include HIV/AIDS treatment, hepatitis C treatment, and oncology products. Gilead Sciences Inc also has a pipeline of products in development for various indications, including HIV, hepatitis B, non-alcoholic steatohepatitis, and respiratory syncytial virus.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company headquartered in Indianapolis, Indiana. The company was founded in 1876 by Colonel Eli Lilly. The company develops and markets products in the areas of diabetes, oncology, immunology, neuroscience, and other areas. Lilly has operations in more than 60 countries and sells products in more than 125 countries. Lilly has been one of the world’s leading innovators in the pharmaceutical industry, with products such as Prozac, Zyprexa, and Cialis. The company has a market cap of 316.18B as of 2022 and a Return on Equity of 45.88%.
– Biogen Inc ($NASDAQ:BIIB)
Biogen Inc. is a global biotechnology company. The company is engaged in the discovery, development, manufacturing and commercialization of therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune diseases. Biogen has a market cap of $39.12B as of 2022 and a return on equity of 14.98%. The company’s products include aducanumab, a monoclonal antibody for the treatment of Alzheimer’s disease; SPINRAZA, a therapeutic agent for the treatment of spinal muscular atrophy; and TYSABRI, a monoclonal antibody for the treatment of multiple sclerosis.
Summary
Amgen Inc. is a biopharmaceutical company that has achieved success in recent years through a stable investment portfolio and strategic acquisitions. In 2019, Amgen acquired Otezla, a biopharmaceutical company specializing in treatments for psoriasis and psoriatic arthritis. Amgen has not made any major changes to their portfolio since 2022, suggesting their current strategy is working. The company is committed to investing in research and development to bring innovative new treatments to the market, while continuing to be a reliable financial asset for investors.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
